HZX-02-059

HZX-02-059 is a potent methuosis inducer and dual-target PIKfyve/tubulin inhibitor with anticancer activity. Methuosis mainly disrupts the balance of endocytosis and exocytosis, forming a large number of vesicles and inducing cell death. HZX-02-059 also induces cell vacuolization, promotes apoptosis, downregulates the p53 pathway, inhibits PI3K/AKT phosphorylation, and inhibits c-Myc and NF-κB transcription[1][2].

Product Specifications

CAS Number

[2240205-30-3]

Product Name Alternative

Methuosis inducer 1

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Methuosis_inducer_1.html

Purity

99.40

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 60°C)

Smiles

CC(C=CC(NC(C1=CC(C(F)(F)F)=CC=C1)=O)=C2)=C2NC3=CC(C4=CN=CC=C4)=NC5=C3C=CN5

Molecular Formula

C27H20F3N5O

Molecular Weight

487.48

References & Citations

[1]Huang W, et al. Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities. J Med Chem. 2018 Jun 28;61 (12) :5424-5434.|[2]Lu Z, et al. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia. Curr Med Sci. 2024 Apr;44 (2) :298-308.